regulator rule pain drug
food drug regulators decide friday recommend sale painkillers linked risk heart attack stroke
food drug administration fda advisory panel verdict hearing evidence days painkillers called inhibitors sold brand names celebrex vioxx vioxx withdrawn shops merck selling fda approval fda decide benefits patients justify increased risks
putting vioxx shelves boost profits merck easier legal battles claim injured drug analysts
merck voluntarily stopped sales vioxx september move caused firm earnings slide earlier merck shares tumbled news company set millions dollars cover cost litigation alarm bells rung note called approve risk heart attack stroke doubled patients drug months inhibitors developed drug companies including merck pfizer users fewer stomach painkillers
pfizer selling celebrex bextra products investigations suggested harmful heart merck announcement reintroduction vioxx caught analysts surprise merck head peter kim withdrew vioxx based knowing alternative therapies changed light reports cardiovascular risk observed approve vioxx unique class drugs marketed kim explained
thursday david graham fda office drug safety told advisory panel inhibitors calculations senate dr graham november vioxx linked american deaths facing stem criticism handling vioxx fda tuesday create independent body oversee safety drugs market european regulators ruled thursday patients heart disease stroke inhibitors european medicines agency doctors cautious drugs patients risk factors heart disease
